Declan Murphy, MB, BCh, on Rate of Equivocal Findings on PSMA PET/CT in Patients With Prostate Cancer
Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.
Declan Murphy, MB, BCh, on the Potential of PSMA PET/CT to Impact Prostate Cancer Outcomes
Declan Murphy, MB, BCh, shares his thoughts on the potential for prostate-specific membrane antigen PET/CT to impact outcomes for patients with localized and high-risk prostate cancers.
Comparing Accuracy Findings from the proPSMA Study for PSMA PET/CT and Conventional Imaging
Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.
Declan Murphy on PSMA Molecules and the Motivation Behind the proPSMA Trial
Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.
Declan Murphy on Theranostics and Future of PSMA PET/CT for Prostate Cancer
Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.